“Retatrutide gives you 24% weight loss.”

The headline −24% is a real number, but it's the best-case corner of the chart: the highest 12 mg dose, measured all the way out at 48 weeks. It's the figure that travels because it's the most impressive, and by the time it reaches a forum post or an ad it has shed every qualifier that made it meaningful.

The same trial tested several lower doses, and they tell a much wider story. The 1 mg arm averaged closer to −9% — still a meaningful result, but a third of the headline. In between sat a spread of outcomes that depended on dose, on how long people stayed on, and on where they started. There was never one number; there was a ladder of them, and the marketing picked the top rung.

Two other things get averaged away. The doses were escalated on different titration schedules before anyone reached their target, so the published averages blend together people who climbed at different speeds. And trial participants were, on average, heavier than many of the people now reading the −24% and imagining it as their own ceiling. Same compound, different bodies, different ramps — folded into a single tidy percentage.

None of this means retatrutide doesn't work; the data is genuinely strong. It means the honest expectation is a range, set by the dose you'll actually run and how long you'll run it, not the trophy number from the top of the curve.